Coreg Cr Capsule, Extended Release
Product Images NDC 80725-388

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Coreg Cr (NDC 80725-388). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Waylis Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Coreg 01)

Chemical structure of carvedilol phosphate dihydrate, showing the molecular arrangement including an indole core, an ether linkage to a hydroxyphenyl group, and associated phosphate and hydrate components.*

FDA Label Image

Figure 1 (Coreg 02)

A line graph comparing percent mortality over a 21-month period between groups labeled Placebo and Carvedilol. Mortality increases steadily over time, with the Placebo group showing higher mortality rates than the Carvedilol group. A p-value of 0.0014 is noted, indicating statistical comparison between groups.*

FDA Label Image

Figure 2 (Coreg 03)

A forest plot illustrating hazard ratios for various patient subgroups including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and use of spironolactone, compared to a reference line at hazard ratio 1.0. Each subgroup is shown with corresponding error bars indicating confidence intervals.*

FDA Label Image

Figure 3 (Coreg 04)

A line graph comparing percentage mortality over 24 months between Carvedilol and placebo groups. The x-axis represents time in months, and the y-axis shows percentage mortality, indicating lower mortality rates in the Carvedilol group compared to placebo, with a p-value of 0.03.*

FDA Label Image

Figure 4 (Coreg 05)

A forest plot chart displaying hazard ratios for various subgroups, including age, sex, timing of randomization post-MI, prior beta-blocker use, Killip class, thrombolytic treatment, PTCA for MI, heart failure status, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure. The horizontal axis shows hazard ratios with a reference line at 1.0, indicating relative risk comparisons across these clinical subgroups.*

FDA Label Image

Figure 5 (Coreg 06)

Two line graphs illustrating change in systolic (SBP) and diastolic blood pressure (DBP) over 24 hours after morning dose of Coreg CR at 20 mg, 40 mg, and 80 mg doses. The x-axis shows time in hours, and the y-axis shows blood pressure change in mmHg, with smoothed regression lines for each dose level.*

FDA Label Image

Principal Display Panel (10 mg Capsule Bottle Label)

Label for Coreg CR 10 mg extended-release capsules by Waylis Therapeutics LLC. The label states each capsule contains 10 mg carvedilol phosphate and includes directions to store at 25°C (77°F). It indicates a 30-capsule quantity with once-a-day dosing and displays the NDC 80725-383-13 along with safety warnings about the membrane seal under the cap.*

FDA Label Image

Principal Display Panel (20 mg Capsule Bottle Label)

Coreg CR 20 mg extended-release capsules packaging label displaying the product name with active ingredient carvedilol phosphate. The label indicates a 30-capsule bottle, oral route, once-a-day dosing, and includes storage instructions, barcode, and distributor information from Waylis Therapeutics LLC.*

FDA Label Image

Principal Display Panel (40 mg Capsule Bottle Label)

Coreg CR 40 mg extended-release capsules label showing the product name, active ingredient carvedilol phosphate, and a 30 capsules count. The label includes instructions for storage at 25°C, a red warning against accepting if the membrane seal is broken, and distribution by Waylis Therapeutics LLC. The label also displays a barcode and notes the dosage as once-a-day oral administration.*

FDA Label Image

Principal Display Panel (80 mg Capsule Bottle Label)

Label for Coreg CR 80 mg extended-release capsules containing carvedilol phosphate, distributed by Waylis Therapeutics LLC. The label indicates a 30-capsule dispenser, with oral route and once-a-day dosing. It includes storage instructions, dosing notes, and a barcode. The label background features light blue and white colors with purple and black text.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.